Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as
neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer